Immix Biopharma Inc (NASDAQ:IMMX) — Market Cap & Net Worth
Market Cap & Net Worth: Immix Biopharma Inc (IMMX)
Immix Biopharma Inc (NASDAQ:IMMX) has a market capitalization of $852.75 Million ($852.75 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9627 globally and #2653 in its home market, demonstrating a -10.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Immix Biopharma Inc's stock price $11.92 by its total outstanding shares 71539314 (71.54 Million). Also see IMMX total assets for a full breakdown of the balance sheet.
Immix Biopharma Inc Market Cap History: 2021 to 2026
Immix Biopharma Inc's market capitalization history from 2021 to 2026. Data shows growth from $254.68 Million to $852.75 Million (28.12% CAGR). Also see IMMX cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Immix Biopharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.03% | #272 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1006 of 3165 |
Weight: Immix Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Immix Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Immix Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check IMMX stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
-1.83x
Immix Biopharma Inc's market cap is -1.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $163.83 Million | $-89.52 Million | -$8.23 Million | -1.83x | N/A |
Competitor Companies of IMMX by Market Capitalization
Companies near Immix Biopharma Inc in the global market cap rankings as of September 18, 2026. Review IMMX tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Immix Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Immix Biopharma Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Immix Biopharma Inc's market cap moved from $254.68 Million to $ 852.75 Million, with a yearly change of 28.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $852.75 Million | +127.92% |
| 2025 | $374.15 Million | +137.73% |
| 2024 | $157.39 Million | -68.21% |
| 2023 | $495.05 Million | +202.18% |
| 2022 | $163.83 Million | -35.67% |
| 2021 | $254.68 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Immix Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $852.75 Million USD |
| MoneyControl | $852.75 Million USD |
| MarketWatch | $852.75 Million USD |
| marketcap.company | $852.75 Million USD |
| Reuters | $852.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.